Drug Therapy

March is Multiple Sclerosis Awareness Month, a time to improve knowledge of and highlight the growing treatment options for progressive types of this degenerative disease.

WEST PALM BEACH, Fla. — Treatment with evobrutinib was nonsuperior to teriflunomide in confirmed disability progression at 12 and 24 weeks for those with relapsing forms of multiple sclerosis, according to a presenter at ACTRIMS 2024.

Treatment with nusinersen was linked to increased motor function and reduction of the neurodegenerative biomarker neurofilament light chain in children with spinal muscular atrophy, according to interim results of a study.

Treatment with viltolarsen at 48 weeks improved pulmonary function in a cohort of pediatric patients with Duchenne muscular dystrophy amenable to exon 53 skipping compared with those receiving standard care.

Treatment with Zolgensma improved motor function in a cohort of children with spinal muscular atrophy, according to a poster at the 2024 MDA Clinical & Scientific Conference.

For young ambulatory boys with Duchenne muscular dystrophy, treatment with pamrevlumab was nonsuperior to placebo after 52 weeks, according to a poster presentation at the 2024 MDA Clinical & Scientific Conference.

Treatment with atogepant was safe, effective and well-tolerated over 12 weeks in those with episodic migraine who failed multiple conventional therapies, with significant reductions in mean monthly migraine days compared with placebo.

Researchers found a complement inhibitor can help reduce rejection.

Quolet Industries has announced the completion of a phase 1 study evaluating a novel, lipid formulation of pure CBD as a potential treatment for various psychiatric and neurologic conditions.

A New York-based biopharmaceutical company has received a grant from Cure Parkinson’s to initiate a phase 2 clinical trial investigating dapansutrile, an oral small molecule, as a disease-modifying therapy for Parkinson’s disease.